Development and Validation of a Self-assessment System Based on a Mobile App to Manage Adult Growth Hormone Deficiency (GrASS)
Growth Hormone Deficiency
About this trial
This is an interventional supportive care trial for Growth Hormone Deficiency focused on measuring Quality Improvement, Quality of Life, Smartphone APP
Eligibility Criteria
Inclusion Criteria:
- Having a documented diagnosis of AGHD, according to the latest Endocrine Society clinical practice guidelines
- Being at least 18 years old
- Having a good Italian understanding
- Owing smartphones with either an Android or iPhone operating system
- Patients with other pituitary deficits will be enrolled only if the other hormonal deficiencies are well controlled by replacement treatments since six months in order to avoid the overlap of effects due to different therapies.
Exclusion Criteria:
1) Patients who do not plan to continue follow-up at the Endocrinology Unit of Modena 2) Patients with a diagnosis of biochemical GHD outside the appropriate clinical context of pituitary disease 3) Patients with major psychiatric diseases, chronic highly invalidating diseases (these patients will be considered not eligible for being enrolled in the study due to the impact of the underlying disease on well-being and daily activities).
Sites / Locations
- Azienda Ospedaliero - Universitaria di Modena
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Ongoing r-hGH therapy
Previous r-hGH therapy
Never treated
Patients on long-term r-hGH therapy. Intervention: Use of "MAGHD App/MAGHD Framework"
Patients previously treated with r-hGH, who had stopped the treatment for any reason (age, concomitant adverse reactions, contraindications or personal will). Intervention: Use of "MAGHD App/MAGHD Framework"
Patients never treated for any reason (according to age, contraindications or lack of patient's consent). Intervention: Use of "MAGHD App/MAGHD Framework"